Skip to main content
SpringerLink
Log in

Does the nadir growth-hormone level predict response to somatostatin-analogue therapy?

  • Practice Point
  • Published:

From Nature Clinical Practice Endocrinology & Metabolism

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Freda PU et al. (2005) Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 90: 4465−4473

  2. Petrossians P et al. (2005) Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol 152: 61–66

    Article  CAS  Google Scholar 

  3. de Herder WW et al. (2005). Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with sandostatin LAR in acromegaly. Eur J Endocrinol 153: 67–71

    Article  CAS  Google Scholar 

  4. Colao A et al. (1996) Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab 81: 2356–2362

    CAS  PubMed  Google Scholar 

  5. Park C et al. (2004) Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous SRIF activity and response to octreotide. Endocr J 51: 227–236

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Professor of Endocrinology, Department of Endocrinology, Centre Hospitalier Universitaire de Liège, University of Liège, Belgium

    Albert Beckers

  2. Research Fellow in Endocrinology, Department of Endocrinology, Centre Hospitalier Universitaire de Liège, University of Liège, Belgium

    Adrian Daly

  3. Staff Clinical Endocrinologist at the Department of Endocrinology, Centre Hospitalier Universitaire de Liège, University of Liège, Belgium

    Patrick Petrossians

Authors
  1. Albert Beckers
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adrian Daly
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Patrick Petrossians
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Albert Beckers.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Beckers, A., Daly, A. & Petrossians, P. Does the nadir growth-hormone level predict response to somatostatin-analogue therapy?. Nat Rev Endocrinol 2, 12–13 (2006). https://doi.org/10.1038/ncpendmet0072

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0072

  • Springer Nature Limited

Search

Navigation